However, the SAM+anti-PD-1 antibody combination had the highest efficacy in controlling tumor growth and progression at day 20 post-tumor injection compared to all groups, as indicated by the least mean tumor volume and tumor weights (Figure 3A,C). Here, PDCD1 is linked to neoplasm.